Celltrion | 068270 - Cash And Equivalent


Celltrion reported KRW56.79B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Celltrion KRW 56.79B 6.92B Mar/2026
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.13B 16M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 886.5M 917.7M Jun/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026